Encephalopathy responsive to thiamine in severe COVID-19 patients
Authors:
Open Access
- 1 July 2021
- journal article
- research article
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 14, 100252
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Wernicke Encephalopathy in COVID-19 Patients: Report of Three CasesFrontiers in Neurology, 2021
- Frequent neurologic manifestations and encephalopathy‐associated morbidity in Covid‐19 patientsAnnals of Clinical and Translational Neurology, 2020
- Neurological involvement of coronavirus disease 2019: a systematic reviewJournal of Neurology, 2020
- Neurologic Features in Severe SARS-CoV-2 InfectionNew England Journal of Medicine, 2020
- Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan DetroitJAMA Network Open, 2020
- Thiamine (vitamin B1) in septic shock: a targeted therapyJournal of Thoracic Disease, 2020
- Wernicke Encephalopathy—Clinical PearlsMayo Clinic Proceedings, 2019
- MR Imaging Findings in Alcoholic and Nonalcoholic Acute Wernicke’s Encephalopathy: A ReviewBioMed Research International, 2014
- Outbreak of Life-Threatening Thiamine Deficiency in Infants in Israel Caused by a Defective Soy-Based FormulaPediatrics, 2005
- Usefulness of CT and MR imaging in the diagnosis of acute Wernicke's encephalopathy.American Journal of Roentgenology, 1998